Market Place
Sourcing Support
Theravance Bio Reports Q3 2024 Results & Shareholder Initiatives
12 Nov 2024 //
PR NEWSWIRE
Theravance Publishes YUPELRI® Spirometry Analysis In Journal
18 Oct 2024 //
PR NEWSWIRE
Theravance Biopharma Reports Q2 2024 Results And Business Update
05 Aug 2024 //
PR NEWSWIRE
Theravance Biopharma to Participate in an Upcoming Investor Conference
25 Jul 2024 //
PR NEWSWIRE
Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI
13 Nov 2023 //
PR NEWSWIRE
Theravance Biopharma, Inc. Initiates $250 Million Capital Return Program
20 Sep 2022 //
PRNEWSWIRE
Theravance Biopharma and Mylan Expand YUPELRI® Dev. & Commercialization
19 Jun 2019 //
PR NEWSWIRE
Theravance Biopharma & Mylan Present Additional YUPELRI® Phase 3
20 May 2019 //
PR NEWSWIRE
Theravance Biopharma & Mylan FDA Approval for YUPELRI™ (revefenacin) inCOPD
10 Nov 2018 //
PR NEWSWIRE
Mylan and Theravance`s COPD treatment gets FDA approval
10 Nov 2018 //
REUTERS
Theravance Biopharma and Mylan Report +ve New Data of Studies of YUPELRI
11 Oct 2018 //
PR NEWSWIRE
Theravance Biopharma and Mylan Report +ve New Data of Studies of YUPELRI
11 Oct 2018 //
PR NEWSWIRE
Theravance Biopharma and Mylan Report +ve New Data of Studies of YUPELRI
11 Oct 2018 //
PR NEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.